Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
American Regent Inc. maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners across a pair of distinct art units. The presence of multiple art units indicates that the company's current filings may span different specialized subfields within the broader pharmaceutical sector, each requiring a tailored technical approach.
The busiest examiner for the portfolio is Baek, Bong-Sook, who is responsible for 1 pending office action. With only a few pending office actions in total, the workload is evenly split among the assigned examiners. This decentralized arrangement means that the prosecution of each application proceeds independently, allowing the company to navigate the specific examination trends of different art units simultaneously without the risk of a single examiner's perspective dominating the active portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
| LIU, TRACY | 1 | 54.5% | +26.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18955379 | TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE | BAEK, BONG-SOOK | — |
| 18955395 | TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE | LIU, TRACY | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18955379 | TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE | BAEK, BONG-SOOK | 1611 | §102§103§112DP | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18955395 | TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE | LIU, TRACY | 1614 | §103§112DP | Non-Final OA | — | Pending | Nov 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmerican Regent Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bong-Sook Baek has the most, with 1 of American Regent Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
